[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"age-related-macular-degeneration-armd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:age-related-macular-degeneration-armd":181},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,80,110,135,160],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100566975","microcurrent-stimulation-therapy-for-intermediate-to-advanced-nonexudative-age-related-macular-degeneration-100566975",false,"NCT06662162","Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration","Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration (i-SIGHT2): a Multicentre, Randomised, Sham-controlled, Double-masked, Clinical Device Trial.","i-SIGHT2","Key Inclusion Criteria:\n\n* Presence of at least one large druse \\>125 microns in diameter due to AMD.\n* BCVA letter score of 35 to 70 letters (inclusive) (Snellen equivalent 6\u002F12 to 6\u002F60 \\[20\u002F40 to 20\u002F200\\])\n\nKey Exclusion Criteria:\n\n* Any implanted electrical device(s) including deep brain stimulator, hearing or visual implants (i.e., cochlear implant, auditory brainstem implant, retinal prostheses), and\u002For cardiac defibrillator\u002Fpacemaker.\n* Implanted metallic device within 20 cm of the Treatment electrode (study eye(s)) and\u002For the grounding electrode (base of the hairline on the back of the neck).\n* Uncontrolled diabetes, defined as glycated haemoglobin (HbA1c) \\>10% (13.3 mmol\u002FL).\n* Current tobacco or tobacco-related product use or history within the past 5 years of heavy smoking (defined as, on average, more than half a pack of cigarettes per day).\n* Known severe allergy to fluorescein dye.\n* Medical diagnosis of severe dry eye defined as requiring either artificial tears more than six (6) times a day or prescription drops (i.e., Restasis, Xiidra, or Cequa).\n* History of seizure disorders, chronic migraines and\u002For cluster headaches.\n* History and\u002For evidence of diabetic retinopathy in either eye as assessed by CF, fundus fluorescein angiography (FA), and OCT, to be confirmed by the Central Reading Centre.\n* Other conditions which pre-dispose to chorioretinal atrophy such as inherited retinal dystrophy (i.e., Stargardt's disease, Best's disease, pattern dystrophy, central areolar choroidal dystrophy, etc.).\n* History and\u002For evidence of exudative AMD in the study eye as assessed by CF, FA (or OCT-A ), and OCT, to be confirmed by Central Reading Centre.\n* GA involving the foveal centre, as assessed by the Central Reading Centre using AF and OCT.\n* History of intravitreal injections for GA (e.g., Syfovre or Izervay).\n* Treatment with photobiomodulation (PBM) therapy or short pulse laser within 12 months prior to screening.\n* Glaucoma requiring ≥3 medications and\u002For drops per day, or history of trabeculectomy.\n* History of any kind of intraocular surgery, excluding cataract surgery performed ≥3 months from Screening.\n* History of yttrium aluminium garnet (YAG) laser posterior capsulotomy \\\u003C1 month from Screening.\n* Visually significant cataracts and\u002For visually significant posterior capsular opacification.\n* History of amblyopia.","ALL","60 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients with intermediate to advanced nonexudative AMD.\n\nParticipants will:\n\n* Undergo an initial loading regimen, followed by 7 maintenance over the course of 11 months.\n* Participants will return monthly through Month 14 (3 months post-last treatment) for evaluation and monitoring.",[27,28,29,30],"Age-Related Macular Degeneration","Age-related Macular Degeneration (ARMD)","Intermediate AMD","Geographic Atrophy Secondary to Age-related Macular Degeneration",[32,29,33,34],"AMD","Dry AMD","Geographic Atrophy","RECRUITING","2026-05-01",{"date":38,"type":39},"2026-05-04","ACTUAL",{"date":41,"type":39},"2025-05-07",{"date":43,"type":21},"2029-12-31",{"name":45,"class":46},"i-Lumen Scientific AUS PTY LTD","INDUSTRY",13,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100618365","phase-1-a-phase-1-study-of-abf-101-in-single--and-multiple-ascending-doses-100618365","NCT07330674","A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses","A Phase 1, Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, and Pharmacokinetics of Orally Administered ABF- 101","Inclusion Criteria:\n\n* Part A and B\n\n  1. Healthy participants, aged between 18 and 50 years\n  2. Provides written, signed, informed consent prior to selection\n  3. BMI of ≥ 18.0 and \\\u003C 32.0 kg\u002Fm2, and body weight between 50 kg and 115 kg, inclusive.\n  4. Vital signs: normal pulse rate and blood pressure.\n  5. Nonsmoker\n  6. Must be willing to abstain from caffeine and alcohol\n  7. Must be willing to avoid strenuous activity\n* Part C\n\n  1. Confirmed diagnosis of AMD\n  2. Male or female ≥50 years of age\n  3. Adequate visual acuity in the non-study eye\n\nExclusion Criteria:\n\n* Part A and B\n\n  1. Any history or presence of cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurologic, psychiatric, systemic, or infectious disease\n  2. Any significant abnormalities detected during ocular examination,\n  3. Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician\n  4. Any drug intake (except paracetamol or contraceptives)\n  5. History or presence alcohol abuse\n  6. History or presence of drug abuse\n  7. Positive HBsAg or anti-HCV antibody, or positive results for HIV\n  8. Blood donation, significant blood loss, or has received a transfusion of any blood or blood products\n  9. Female participants who are breastfeeding.\n  10. Female participants must not be pregnant or at risk to become pregnant during the study. Male and female participants must agree to use highly effective contraception\n  11. Participant who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language barrier or poor mental development\n\nPart C\n\n1. Evidence of CNV due to any cause other than AMD\n2. History of vitreoretinal surgery\n3. Significant ocular diseases that may interfere with the study\n4. Significantly impaired renal or hepatic function\n5. Use of immunosuppressive drugs\n6. Use of any investigational agent or participation in any other clinical trial of an investigational agent or investigational therapy\n7. History of severe drug allergies or drug hypersensitivity syndrome\n8. Undiagnosed acute illness first observed during screening or between screening and baseline, or severe concurrent medical conditions that, in the investigator's judgment, represent a safety concern.\n9. Severe cardiac disease.\n10. QTc ≥450 msec or participants with a history of risk factors or other clinically significant ECG abnormalities\n11. Stroke or transient ischemic attack\n12. Any major surgical procedure w\n13. Serious active infection, other serious medical condition or any other condition that would impair the ability of the participant to administer the investigational drug or to adhere to the study protocol requirements\n14. Presence of any condition which, in the judgment of the investigator, would prevent the participant from completing the study",true,"18 Years","50 Years",{"count":59,"type":21},68,[61],"PHASE1","This is a Phase 1 study to evaluate the safety, tolerability, PK, and PD of ABF-101 in healthy participants and participants with age-related macular degeneration (AMD).",[64,65],"Age Related Macular Degeneration (ARMD)","AMD - Age-Related Macular Degeneration",[67,32,68],"ABF-101","NOX","2026-02-04",{"date":71,"type":39},"2026-02-06",{"date":73,"type":21},"2026-02",{"date":75,"type":21},"2027-12",{"name":77,"class":78},"Aptabio Therapeutics, Inc.","INDIV",1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":105,"leadSponsor":107,"locationsCount":79},"100607380","phase-4-long-term-efficacy-of-faricimab-using-a-treat-and-extend-regimen-for-type-3-macular-neovascularization-100607380","NCT07187804","Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization","Inclusion Criteria:\n\n\\[General\\]\n\n* Signed Informed Consent Form\n* Age \\> 50 years at the time of signing Informed Consent Form\n* Participants who are able to comply with the study protocol, in the investigator's judgment\n* For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception (will be defined in details in protocol)\n\n\\[Ocular\\]\n\n* BCVA that is equal or higher than 24 Early Treatment Diabetic Retinopathy Study letters on Screening Day\u002F Day 0.\n* Confirmed diagnosis, by the investigator, of symptomatic type 3 neovascularization based on sufficiently clear ocular media and adequate pupillary dilatation allowing acquisition of good quality retinal images for confirmation.\n* Treatment naive participants\n\nExclusion Criteria:\n\n\\[General\\]\n\n* Treatment with investigational therapy (device, drug, or traditional medicine with the exception of vitamins and minerals) within 3 months prior to initiation of study treatment on study Day 1\n* Any major illness or major surgical procedure within 1 month before screening\n* Active cancer within the 12 months prior to study Day 1 except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, and prostate cancer with a Gleason score of \\\u003C 6 (Grade Group of 1) and a stable prostate-specific antigen for \\>12 months\n* Continuous use of any medications and treatments (which will be indicated in the Prohibited Therapy section in protocol)\n* Systemic treatment for suspected or active systemic infection on study Day 1\n* Uncontrolled blood pressure, defined as systolic blood pressure \\> 180 mmHg and\u002For diastolic blood pressure \\> 100 mmHg while the participant is at rest on study Day 1\n* History of stroke (cerebral vascular accident) or myocardial infarction within 6 months prior to study Day 1\n* History of other disease, metabolic dysfunction, physical examination finding, or historical or current clinical laboratory findings giving reasonable suspicion of a condition that contraindicates the use of the investigational drug or that might affect interpretation of the results of the study or renders the participant at high risk for treatment complications in the opinion of the investigator\n* History of severe allergic reaction or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of the faricimab injection, study-related procedure preparations (including fluorescein and indocyanine green dyes), dilating drops, or any of the anesthetic and antimicrobial preparations used by a participant during the study\n* Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 28 days after the final dose of faricimab\n\n\\[Ocular\\]\n\n* Significant media opacities, including cataract, in the study eye that might interfere with visual acuity, assessment of safety, or fundus photography.\n* Any concurrent ocular condition in the study eye which, in the opinion of the investigator, could either increase the risk to the patient beyond what is to be expected from standard procedures of intraocular injection, or which otherwise may interfere with the injection procedure or with evaluation of efficacy or safety.\n\nAny ocular or periocular infection within the last 2 weeks prior to Screening in either eye.\n\n* Any history of uveitis in either eye.\n* Presence of definite chorioretional anastomosis\n* Subretinal hemorrhage that is either 50% or more of the total lesion area, or if the blood is under the fovea and is 1 or more disc areas in size in the study eye. (If the blood is under the fovea, then the fovea must be surrounded 270 degrees by visible macular neovascularization.)\n* Scar or fibrosis, making up \\> 50% of total lesion in the study eye.\n* Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.\n* Presence of retinal pigment epithelial tears or rips involving the macula in the study eye.\n* History or clinical evidence of diabetic retinopathy, diabetic macular edema or any other vascular disease affecting the retina, other than AMD, in either eye.\n* Any concurrent intraocular condition in the study eye (e.g. cataract) that, in the opinion of the investigator, could require either medical or surgical intervention during the 76 week study period.\n* Prior vitrectomy in the study eye\n* Any history of macular hole of stage 2 and above in the study eye.\n* Any intraocular or periocular surgery within 3 months of Day 1 on the study eye, except lid surgery, which may not have taken place within 1 month of day 1, as long as it's unlikely to interfere with the injection.\n* Prior trabeculectomy or other filtration surgery in the study eye.\n* Uncontrolled glaucoma (defined as intraocular pressure ≥ 25 mmHg despite treatment with antiglaucoma medication) in the study eye.\n* Active intraocular inflammation in either eye.\n* Active ocular or periocular infection in either eye.\n* Aphakia or pseudophakia with absence of posterior capsule (unless it occurred as a result of an yttrium aluminum garnet \\[YAG\\] posterior capsulotomy) in the study eye.",{"count":87,"type":21},30,[89],"PHASE4","Type 3 macular neovascularization (MNV) is a subtype of neovascular age-related macular degeneration accounting for 10-20% of cases, notable for high rates of bilateral involvement and risk of profound vision loss, particularly if undertreated. Early and proactive therapy is crucial to prevent progression and preserve vision.\n\nFaricimab offers potential advantages in this setting. Eyes with type 3 MNV often show thin choroid, reticular pseudodrusen, and high GA risk, reflecting compromised choroidal perfusion. While anti-vascular endothelial growth factor (VEGF) agents suppress neovascularization, prolonged VEGF blockade may impair choriocapillaris health. Ang-2 inhibition, by promoting Tie2 activation and vascular stability, may protect choriocapillaris and reduce widespread retinal edema and hemorrhages observed in type 3 MNV.\n\nFinally, while treat-and-extend is widely used in practice, existing trials (TENAYA, LUCERNE) applied broader extension intervals than typically used clinically. In type 3 MNV, where undertreatment carries severe consequences, a more stringent faricimab-based treat-and-extend regimen with 2-week interval adjustments warrants investigation.",[28,92,93],"Choroidal Neovascularization","Anti-vascular Endothelial Growth Factor",[95,96,97,98,99],"Age-related macular degeneration","Type 3 macular neovascularization","Retinal angiomatous proliferation","Faricimab","Treat and extend","NOT_YET_RECRUITING","2025-09-19",{"date":103,"type":39},"2025-09-23",{"date":103,"type":21},{"date":106,"type":21},"2028-09-22",{"name":108,"class":109},"Kim's Eye Hospital","OTHER",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":55,"sex":17,"minAge":116,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":4},"100593186","research-on-a-new-intelligent-mobile-screening-and-diagnosis-pattern-for-ocular-diseases-100593186","NCT07003165","Research on a New Intelligent Mobile Screening and Diagnosis Pattern for Ocular Diseases","Inclusion Criteria:\n\n* Age ≥ 7 years\n* Voluntary informed consent\n\nExclusion Criteria:\n\n-Inability to complete the required examinations with the help of others due to old age, infirmity, poor general condition, etc.","7 Years",{"count":118,"type":21},15000,"OBSERVATIONAL","The global distribution of primary ophthalmic medical resources is uneven, and the traditional eye disease screening model has problems such as low efficiency, high cost and limited coverage. With the development of artificial intelligence and other technologies, it provides technical support for the construction of intelligent mobile screening model for eye diseases. The investigator's team has developed the 5G intelligent ophthalmic vehicle and served tens of thousands of people in 108 cities nationwide, initially verifying the feasibility of the new intelligent mobile screening model. However, the application effect, acceptance and influencing factors of this model in different regions are not clear, and there is a lack of economic benefit analysis based on real-world data. In this study, the investigators will conduct a cross-sectional study of large-scale population screening for blinding eye diseases in grassroots areas through the smart mobile screening model, focusing on the screening effectiveness and cost-effectiveness of the smart mobile screening model, integrating real-world multimodal eye health data, developing multiple smart screening analysis models, and exploring its adaptability and direction of improvement in grassroots areas.",[122,123,124,125,64],"Ophthalmic Diseases (Specific Types Not Restricted)","Cataract","Refraction Error","Diabetic Retinopathy (DR)","2025-06-03",{"date":128,"type":39},"2025-06-04",{"date":130,"type":21},"2025-07",{"date":132,"type":21},"2029-05",{"name":134,"class":109},"Zhongshan Ophthalmic Center, Sun Yat-sen University",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":145,"conditions":146,"keywords":147,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":79},"100568647","phase-4-switching-to-aflibercept-8mg-in-patients-showing-limited-response-to-previous-treatment-100568647","NCT06683950","Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment","Efficacy of Switching to Aflibercept 8mg in Patients With Neovascular AMD Showing Limited Response to Faricimab or Aflibercept 2mg","Inclusion Criteria:\n\n* Willing, committed, and able to return for ALL clinic visits and complete all study related procedures.\n* Able to read, (or, if unable to read due to visual impairment, be read to verbatim by the person administering the informed consent or a family member) understand and willing to sign the informed consent form.\n* Signed informed consent\n* Patients aged 50 years or older\n* Patients diagnosed with neovascular AMD or PCV\n* Patients underwent faricimab or aflibercept 2mg injections with an inverval of 4 to 16 weeks\n* Patients who continued to show persistent subretinal fluid (SRF) or intraretinal fluid (IRF) despite receiving two consecutive faricimab or aflibercept 2mg injections at the same injection interval.\n* In cases where the central retinal thickness did not decrease by more than 50 μm during two consecutive treatments prior to inclusion in the study\n* ETDRS BCVA letter score ≥25 letters (approximately 20\u002F320 or better) in the study eye\n\nExclusion Criteria:\n\n* Any prior ocular (in the study eye) or systemic treatment or surgery for neovascular AMD except dietary supplements or vitamins.\n* Significant media opacities, including cataract, in the study eye that might interfere with visual acuity, assessment of safety, or fundus photography.\n* Any concurrent ocular condition in the study eye which, in the opinion of the investigator, could either increase the risk to the patient beyond what is to be expected from standard procedures of intraocular injection, or which otherwise may interfere with the injection procedure or with evaluation of efficacy or safety.\n* Any ocular or periocular infection within the last 2 weeks prior to Screening in either eye.\n* Any history of uveitis in either eye.\n* Presence of definite chorioretional anastomosis\n* Scar or fibrosis, making up \\> 50% of total lesion in the study eye.\n* Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.\n* Presence of retinal pigment epithelial tears or rips involving the macula in the study eye.\n* History or clinical evidence of diabetic retinopathy, diabetic macular edema or any other vascular disease affecting the retina, other than AMD, in either eye.\n* Any concurrent intraocular condition in the study eye (e.g. cataract) that, in the opinion of the investigator, could require either medical or surgical intervention during the 76 week study period.\n* Prior vitrectomy in the study eye\n* Any history of macular hole of stage 2 and above in the study eye.\n* Any intraocular or periocular surgery within 3 months of Day 1 on the study eye, except lid surgery, which may not have taken place within 1 month of day 1, as long as its unlikely to interfere with the injection.\n* Prior trabeculectomy or other filtration surgery in the study eye.\n* Uncontrolled glaucoma (defined as intraocular pressure ≥ 25 mmHg despite treatment with antiglaucoma medication) in the study eye.\n* Active intraocular inflammation in either eye.\n* Active ocular or periocular infection in either eye.\n* Aphakia or pseudophakia with absence of posterior capsule (unless it occurred as a result of a yttrium aluminum garnet \\[YAG\\] posterior capsulotomy) in the study eye.\n* History of corneal transplant or corneal dystrophy in the study eye.",{"count":143,"type":21},40,[89],"The treatment landscape for neovascular AMD has evolved with various anti-VEGF agents since 2006. Ranibizumab initially led the way, but its limited efficacy in reducing retinal edema paved the way for aflibercept in 2011, which became globally popular for its effectiveness and safety. Yet, aflibercept did not fully meet all patients' needs. In 2019, brolucizumab showed promising anatomical results but had higher risks of inflammation, limiting its use. Faricimab, introduced in 2022, aimed for longer-lasting effects by targeting VEGF-A and angiopoietin 2. Though it required fewer injections, questions remain about its long-term efficacy compared to aflibercept.\n\nDespite recent advancements, no agent has established itself as the new standard since aflibercept's introduction, leaving significant unmet needs. Aflibercept 8mg, approved in 2023, has shown promise by matching long-term visual outcomes of aflibercept 2mg with fewer injections and comparable safety. This study examines the effects of switching to aflibercept 8mg for patients with a limited response to previous treatments, addressing the potential for aflibercept 8mg to meet current needs more effectively and providing timely data for its global rollout.",[28],[95,148,149,150,98,151],"Choroidal neovascularization","Aflibercept","Aflibercept 8mg","Refractory","2024-11-09",{"date":154,"type":39},"2024-11-12",{"date":156,"type":39},"2024-10-21",{"date":158,"type":21},"2026-05-31",{"name":108,"class":109},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":4},"100560896","prediction-model-of-treatment-efficacy-for-age-related-macular-degeneration-based-on-multi-source-imaging-modalities-100560896","NCT06583109","Prediction Model of Treatment Efficacy for Age-related Macular Degeneration Based on Multi-source Imaging Modalities","Establishment and Application of Prediction Model of Treatment Efficacy for Age-related Macular Degeneration Based on Multi-source Imaging Modalities","Inclusion Criteria:\n\n* Patients diagnosed with nAMD by ophthalmic examinations including OCT, OCTA, FFA and ICGA;\n* Complete clinical data and imaging data of patients were available at baseline, 3 months and 1 year after anti-VEGF treatment.\n\nExclusion Criteria:\n\n* Medical records showed other diseases affecting visual function or fundus imaging, such as macular edema, glaucoma, ocular trauma, etc;\n* Medical records showed that two or more macular lesions coexist in the affected eye;\n* Medical records showed that patients received other treatments within 1 year of anti-VEGF therapy, such as intraocular laser therapy or ocular surgery;\n* Medical records showed that there were ocular media opacity, dense macular hemorrhage, or severe macular atrophy, resulting in the inability to accurately measure the required parameters;\n* Medical records showed the use of drugs known to cause retinal toxicity, or a history of radiation exposure.",{"count":168,"type":21},2600,"Age-related macular degeneration (AMD) is one of the main causes of blindness in the elderly population. Intraocular injection of anti-VEGF drugs for neovascular AMD (nAMD) is the main treatment method at present. However, patients have different responses to anti-VEGF therapy, and some patients do not respond well to short - and long-term treatment.\n\nIn this study, a retrospective study was adopted to collate and analyze the clinical data and imaging data of nAMD in the past, and to extract the imaging features from the multimodal modalities before and after treatment for deep learning, and to evaluate and quantify the clinical features, and to construct two multi-source feature models for predicting the short-term and long-term prognosis of nAMD patients. By verifying the accuracy of the model to predict the curative effect, the classification efficiency of the above characteristic models was compared, and the optimal model was selected. Its clinical application value was evaluated by calibration curve and decision curve. In addition, patients with poor treatment response in the study cohort were retrospectively analyzed, and the efficacy and safety of the combination of other treatment options in the actual clinic were analyzed. The purpose of this study is to provide scientific basis for early prediction, dynamic monitoring and optimization of overall treatment strategies for nAMD.",[28],"2024-09-01",{"date":173,"type":39},"2024-09-03",{"date":175,"type":21},"2024-10-01",{"date":177,"type":21},"2026-06-01",{"name":179,"class":180},"Beijing Hospital","OTHER_GOV","Age-Related Macular Degeneration (ARMD)"]